Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Microbicides news

Show

From To
IPM's dapivirine ring may offer significant HIV protection when used consistently

New data analyses announced at the AIDS 2016 conference today provide additional evidence suggesting that the monthly dapivirine vaginal ring developed by the nonprofit International Partnership for Microbicides (IPM) provides significant protection against HIV infection in women when used consistently. The new data were released as two open-label studies of the ring begin and as IPM pursues regulatory approvals for the product for its use in developing countries.

Published
18 July 2016
From
International Partnership for Microbicides
Treatment Action Group: Pipeline Report 2016

Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.

Published
15 July 2016
From
Treatment Action Group
Five Exciting HIV Prevention Studies We’re Paying Attention To

What’s on the horizon of HIV prevention? Here are five clinical trials to pay attention to, if you’re interested in what the next big breakthrough in the HIV prevention field may be.

Published
30 June 2016
From
BETA blog
Can a gel to prevent HIV be applied as a lube?

Rectal microbicide gels, applied either daily or before and after sex, are currently being investigated as an option for HIV pre-exposure prophylaxis (PrEP). Given that many people who have anal lready use lube, one hope is for an HIV-prevention product that people could essentially use in place of a lube. But can gels provide enough coverage across rectal tissue if people don’t use an applicator?

Published
18 March 2016
From
BETA blog
NIAID to Fund Further Study of Dapivirine Vaginal Ring for HIV Prevention

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced today that it would move forward with an open-label extension study of an HIV prevention tool for women: a silicone ring that continuously releases the experimental antiretroviral drug dapivirine in the vagina. The new study builds on recently announced findings from the ASPIRE trial which found that the dapivirine ring safely provided a modest level of protection against HIV infection in sub-Saharan African women.

Published
14 March 2016
From
National Institute of Allergy and Infectious Diseases
Vaginal ring for HIV prevention: a few details would have elevated good coverage to great

Analysis of BuzzFeed's coverage of vaginal ring studies.

Published
01 March 2016
From
Health News Review
Why a new vaginal ring could be a game-changer in HIV prevention

This is the first time two phase-three clinical trials have confirmed statistically significant efficacy for a microbicide to prevent HIV. The dapivirine ring was designed to offer potentially long-acting protection against HIV through slow, continuous delivery of dapivirine into the vaginal tissues over the course of four weeks. But there are still several more steps that need to be followed before the ring becomes available to women.

Published
01 March 2016
From
The Conversation
‘On-demand’ rectal microbicide gel has reasonable tolerability and acceptability – daily less so

Results from the MTN-017 study of 1% tenofovir gel as a rectal microbicide were presented to the Conference on Retroviruses and Opportunistic Infections (CROI 2016) on

Published
28 February 2016
By
Gus Cairns
Modern HIV Prevention: What’s Next For Women?

The vaginal ring is one more addition to an already exciting array of antiretroviral-based biomedical options in the prevention toolbox that has ushered in a new era in HIV prevention.

Published
26 February 2016
From
International AIDS Society
More investment needed in developing female-controlled HIV prevention options

Results from two large-scale studies of a vaginal ring that releases the antiretroviral medicine dapivirine to prevent HIV among women have shown protection of around 30% against HIV. The results are encouraging and show the urgent need to expand investment in research and development for female-controlled methods of HIV prevention. Although less effective than hoped for, the results are the first to show that a sustained release mechanism for antiretroviral medicine is feasible, safe and partially effective in preventing HIV infection among women. Follow-up studies are needed to build on these results and there is a need to better understand how to optimize the HIV prevention effect and support adherence.

Published
24 February 2016
From
UNAIDS
← First12345...22Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close